We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+35.04%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$1.94B
AUM Growth
+$181M
Cap. Flow
-$1.32M
Cap. Flow %
-0.07%
Top 10 Hldgs %
41.59%
Holding
123
New
29
Increased
30
Reduced
25
Closed
18

Top Buys

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$28.3M
2
ANAB icon
AnaptysBio
ANAB
+$26.6M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$20.4M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$19.6M
5
ERAS icon
Erasca
ERAS
+$17.1M

Top Sells

Rank Stock Value
1
VTYX
Ventyx Biosciences
VTYX
+$58.6M
2
WVE icon
Wave Life Sciences
WVE
+$16.9M
3
CGEM icon
Cullinan Oncology
CGEM
+$14.8M
4
ACLX
Arcellx
ACLX
+$14.2M
5
BBIO icon
BridgeBio Pharma
BBIO
+$12.3M

Sector Composition

Rank Sector Weight
1 Healthcare 85.51%
2 Financials 0.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
51
PUT
Revolution Medicines
RVMD
$39.6B
$9.72M 0.5%
+100,000
New +$10.1M
IBRX icon
52
PUT
ImmunityBio
IBRX
$8.04B
$9.59M 0.5%
+1,250,000
New +$8.56M
JBIO
53
Jade Biosciences
JBIO
$1.27B
$8.99M 0.46%
639,956
-75,000
-10% -$1.09M
TVTX icon
54
Travere Therapeutics
TVTX
$5.27B
$8.91M 0.46%
300,000
– –
NAMS icon
55
NewAmsterdam Pharma
NAMS
$3.7B
$8.8M 0.45%
275,000
– –
KRRO icon
56
Korro Bio
KRRO
$177M
$8M 0.41%
+706,904
New +$7.78M
CRSP icon
57
CRISPR Therapeutics
CRSP
$4.71B
$7.14M 0.37%
+150,000
New +$7.91M
SGP
58
SpyGlass Pharma
SGP
$661M
$6.48M 0.33%
+250,000
New +$6.73M
NVO
59
CALL
Novo Nordisk
NVO
$223B
$6.43M 0.33%
+175,000
New +$8.29M
CMPS
60
Compass Pathways
CMPS
$1.67B
$6.13M 0.32%
1,108,483
+908,483
+454% +$6.11M
IBIO icon
61
iBio
IBIO
$68.6M
$5.9M 0.3%
3,107,200
+1,050,000
+51% +$2.44M
ESTA icon
62
Establishment Labs
ESTA
$2.72B
$5.68M 0.29%
100,000
-100,000
-50% -$6.83M
AVR
63
Anteris Technologies
AVR
$823M
$5.06M 0.26%
912,397
+425,713
+87% +$2.45M
NAMSW icon
64
NewAmsterdam Pharma Warrant
NAMSW
$4.91M 0.25%
245,000
– –
QURE icon
65
CALL
uniQure
QURE
$2.77B
$4.91M 0.25%
300,000
-500,000
-63% -$10.1M
VRDN icon
66
Viridian Therapeutics
VRDN
$1.99B
$4.89M 0.25%
250,000
– –
CLYM
67
Climb Bio
CLYM
$727M
$4.79M 0.25%
700,000
-600,000
-46% -$3.46M
RZLT icon
68
Rezolute
RZLT
$444M
$4.72M 0.24%
1,547,641
-803,503
-34% -$2.41M
SGMT icon
69
Sagimet Biosciences
SGMT
$483M
$4.54M 0.23%
868,020
-280,225
-24% -$1.56M
MBX
70
MBX Biosciences
MBX
$2.99B
$4.48M 0.23%
150,000
-100,000
-40% -$3.4M
TSHA icon
71
Taysha Gene Therapies
TSHA
$1.71B
$4.47M 0.23%
1,000,000
-2,300,000
-70% -$10.7M
MANE
72
Veradermics Inc
MANE
$4.65B
$4.42M 0.23%
+70,000
New +$3.53M
GENB
73
Generate Biomedicines
GENB
$1.74B
$4.38M 0.23%
+350,000
New +$4.27M
DNTH icon
74
CALL
Dianthus Therapeutics
DNTH
$5.77B
$4.2M 0.22%
+50,000
New +$2.9M
ENGN icon
75
enGene Therapeutics
ENGN
$122M
$4.16M 0.21%
610,370
-33,000
-5% -$294K
1 2
3
4 5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q1 2026 Portfolio in Review

As of Q1 2026, Affinity Asset Advisors held 123 positions worth $1.94B, up 10% from $1.76B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Affinity Asset Advisors's Q1 2026 filing shows 29 new, 30 increased, 25 reduced and 18 closed positions. Its largest new stake was Enliven Therapeutics: 586,904 shares worth $23M. The largest sale was Ventyx Biosciences, an estimated $58.6M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 77% a quarter earlier, followed by Financials.

  • Affinity Asset Advisors's largest Q1 2026 buy was Enliven Therapeutics: 586,904 shares worth $23M.
  • Affinity Asset Advisors added most to Roivant Sciences in Q1 2026, an estimated $28.3M increase.
  • Affinity Asset Advisors's biggest Q1 2026 reduction was Wave Life Sciences, cutting an estimated $16.9M.
  • Affinity Asset Advisors fully exited Ventyx Biosciences in Q1 2026, selling an estimated $58.6M.
  • Affinity Asset Advisors's ten largest holdings make up 42% of its $1.94B portfolio in Q1 2026.
  • Affinity Asset Advisors opened 29 new positions and closed 18 in Q1 2026.
  • Affinity Asset Advisors's portfolio value rose 10% quarter-over-quarter to $1.94B.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.